Treatment of Oral Pemphigus
Start with oral prednisolone 1 mg/kg/day combined with an adjuvant immunosuppressant (azathioprine 2-3 mg/kg/day, mycophenolate mofetil 2-3 g/day, or rituximab), as this combination approach achieves superior remission rates compared to corticosteroids alone. 1
First-Line Systemic Therapy
Corticosteroid Dosing
- Initiate oral prednisolone at 1 mg/kg/day for most cases of oral pemphigus vulgaris 1
- For milder oral-only disease, consider starting at 0.5-1 mg/kg/day 1
- If no response within 5-7 days, increase dose by 50-100% increments until disease control is achieved 1
- Clinical improvement typically occurs within days, with cessation of new lesions averaging 2-3 weeks and complete healing taking 3-8 weeks 1
Critical Evidence on Combination Therapy
The landmark 2017 RCT demonstrated that rituximab combined with short-term prednisolone achieved 89% complete remission off all treatment at 2 years, compared to only 28% with prednisolone alone 1. This represents the strongest evidence for adjuvant therapy in pemphigus.
Adjuvant Immunosuppressants (Start Simultaneously)
Combine corticosteroids with one of the following 1:
- Azathioprine 2-3 mg/kg/day (check TPMT levels first) 1
- Mycophenolate mofetil 2-3 g/day 1
- Rituximab (2 × 1 g infusions, 2 weeks apart using rheumatoid arthritis protocol) 1
Important caveat: Adjuvant drugs are more important for remission maintenance than induction due to delayed onset of action 1. However, starting them early prevents the need for prolonged high-dose corticosteroids and reduces steroid-related mortality, which accounts for up to 77% of pemphigus deaths 1.
Topical Therapy for Oral Lesions
Topical Corticosteroids
While evidence for additional benefit is limited when patients are on systemic therapy, topical corticosteroids are frequently used as adjunctive treatment 1:
- Betamethasone sodium phosphate 0.5 mg dissolved in 10 mL water as 2-3 minute rinse-and-spit solution 1-4 times daily 1
- Fluticasone propionate nasules diluted in 10 mL water twice daily 1
- Clobetasol 0.05% ointment mixed in 50% Orabase applied twice weekly to localized lesions on dried mucosa 1
Alternative Topical Agent
- Tacrolimus 0.1% ointment applied twice daily showed comparable efficacy to triamcinolone acetonide 0.1% paste in a split-mouth trial 1
Corticosteroid Tapering Strategy
Once remission is achieved (no new blisters and healing of majority of lesions) 1:
- Gradually taper prednisolone with goal of reducing to ≤10 mg daily 1
- One successful protocol tapered from 1 mg/kg/day to 40 mg over 4-6 weeks, then gradually to 5 mg on alternate days over 9 months 2
- Do not withdraw treatment prematurely: 47% of patients relapse when treatment is stopped after only 1 year 1
Second-Line Therapy
If treatment failure occurs with first-line adjuvant drug 1:
- Switch to an alternate corticosteroid-sparing agent (azathioprine, mycophenolate mofetil, or rituximab) 1
- Consider mycophenolic acid 720-1080 mg twice daily if gastrointestinal symptoms from mycophenolate mofetil 1
Treatment failure is defined as: continued disease activity despite 3 weeks of prednisolone 1.5 mg/kg/day, or 12 weeks of azathioprine 2.5 mg/kg/day (with normal TPMT), mycophenolate mofetil 1.5 g twice daily, cyclophosphamide 2 mg/kg/day, or methotrexate 20 mg/week 1
Third-Line Options
For refractory cases, consider multidisciplinary team assessment for 1:
- Cyclophosphamide
- Intravenous immunoglobulin
- Immunoadsorption
- Methotrexate
- Plasmapheresis or plasma exchange
Critical Safety Considerations
- Assess osteoporosis risk immediately upon starting corticosteroids 1
- Patients receiving prednisolone alone experience significantly more side effects than those using azathioprine as adjuvant (80% vs 50%) 2
- High-quality oral hygiene is essential, as painful erosions inhibit tooth brushing, leading to plaque accumulation that compounds inflammation 1
- Patients with pemphigus vulgaris have worse periodontal status than matched controls 1
Evidence on Moderate-Dose Approach
Research specifically on oral pemphigus demonstrates that moderate doses of steroids alone (40 mg prednisone equivalent) are effective in controlling oral disease 3. However, this conflicts with the stronger 2017 evidence showing combination therapy superiority 1. Given that oral pemphigus likely represents an initial stage that can become generalized 3, and considering the landmark RCT data, the combination approach with adjuvant therapy is preferred to prevent disease progression and reduce long-term steroid burden.